Title: bluebird bio Announces Positive Phase 1/2 Clinical Trial Data for Gene Therapy
In recent financial reports submitted to the Securities and Exchange Committee (SEC) in an 8-K filing, bluebird bio, Inc. (NASDAQ: BLUE), a leading biotech company, has provided an update on their ...
pharmaphorum19h
PTC gets green light for gene therapy Upstaza in EU
PTC Therapeutic's Upstaza gene therapy for patients with genetic disorder ... as well as the UK. Most tellingly, bluebird bio said last year it would exit the European market altogether, saying ...